Literature DB >> 6777433

The activity of polymorphonuclear leukocyte neutral proteinases and their inhibitors in patients with psoriasis treated with a continuous peritoneal dialysis.

W Glinski, Z Zarebska, S Jabłonska, J Imiela, J Nosarzewski.   

Abstract

3 of 16 patients with extensive psoriasis have been completely cleared of skin lesions within 2-3 weeks of continuous peritoneal dialysis, and 2 of them up to 2 mo after termination of therapy. In 5 cases there was a great improvement of psoriatic lesions and in 6 remaining cases only a slight improvement was found. The remission of psoriasis was correlated with extremely high polymorphonuclear leukocyte depletion through the peritoneal cavity in a short time. Neutral serine proteinases were extracted from polymorphonuclear leukocytes and quantitated. The quantity of enzymes in the cells recovered from peritoneal dialysates was found to decrease with duration of treatment, and it was 2-5 times lower than amounts of neutral proteinases extracted from peripheral blood polymorphonuclear leukocytes of psoriatics and normals. The enzyme content per polymorphonuclear leukocyte of patients with active psoriasis was significantly higher (2-fold) than that in inactive psoriasis and in normal controls. Proteinase activity was also found in the sera of psoriatics and normals, as well as in the peritoneal dialysates. However, this activity appeared to be about 30-50 times lower than serum inhibitory activity against neutral proteinases. The concentration of neutral proteinase inhibitors in 5 of 17 sera of patients with psoriasis was significantly lower than that in normal sera. These data indicate that the depletion of activated PMNL with increased amounts of neutral proteinases may account for the beneficial effect of peritoneal dialysis in the clearing of psoriatic lesions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6777433     DOI: 10.1111/1523-1747.ep12524244

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Leukopheresis for treatment of psoriasis: is therapeutical benefit related to reduced activities of neutral proteinases of polymorphonuclear leukocytes?

Authors:  W Gliński; D Barszcz; S Jabłońska; Z Zarebska; M Tigałonowa; E Janczura
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

2.  Alpha 1-proteinase inhibitor in psoriasis: reduced activity in symptom-free patients and during flare.

Authors:  D Barszcz; Z Zarebska; M Glińska-Ferenz; S Jabłońska; M Tigałonowa; W Gliński
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

3.  Plasma exchange and leukapheresis in psoriasis--no effect?

Authors:  G Liedén; M Skogh
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

4.  Enhanced chemiluminescence production by phagocytosing neutrophils in psoriasis.

Authors:  F J Bloomfield; M M Young
Journal:  Inflammation       Date:  1988-04       Impact factor: 4.092

5.  Psoriatic leukotactic factor. Further physicochemical characterization and effect on the epidermal cells.

Authors:  H Tagami; Y Kitano; S Suehisa; T Oku; M Yamada
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

6.  Growth hormone levels in psoriasis.

Authors:  G C Priestley; D J Gawkrodger; J Seth; S M Going; J A Hunter
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.